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Objectives: The 21-gene Breast Cancer Test (Oncotype DX®) is a validated diag-
nostic test that predicts the likelihood of adjuvant chemotherapy benefit and breast 
cancer recurrence in selected patients with early-stage breast cancer. A previous 
cost-effectiveness analysis of this test versus standard French clinical practice was 
published in 2012. Since then, docetaxel is no longer reimbursed on top of the 
diagnosis related groups (DRGs). The objective of this study was to update the cost-
effectiveness analysis considering this change. MethOds: The cost-effectiveness 
analysis was conducted using a Markov model including three health states (sur-
vival without recurrence, metastatic recurrence at ten years and death). Previous 
cost analyses were updated in order to assess the current overall costs of chemo-
therapy in public and private hospitals, considering that doxetaxel is not anymore 
reimbursed on top of DRGs. Unit costs were updated to 2015 values and other model 
parameters were collected from published literature. This study was conducted 
from the societal perspective. Deterministic sensitivity analyses were conducted to 
identify key drivers of the results. Results: Chemotherapy costs (standard devia-
tion) per patient were estimated at € 10,917 from the societal perspectivein public 
hospitals. The incremental number of life years gained over 30 years was 0.15; the 
incremental number of QALYs gained was 0.14. Using the test was found to be cost-
effective versus usual care with a cost per QALY ratio of € 3,453 in public hospitals 
(€ 4,147 in private) from public perspective and a dominant strategy with a net cost-
saving per patient of € 658 in public hospitals (€ 449 in private) when considering 
costs of absenteeism. cOnclusiOns: While the cost of chemotherapy decreased 
considerably after the inclusion of docetaxel in the DRGs, the use of the 21-gene test 
is still cost-effective compared to usual care in French public and private hospitals 
from a societal perspective.
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Objectives: To conduct a cost-effectiveness analysis of primary and second-
ary prophylaxis (PP & SP) with long acting granulocyte colony-stimulating fac-
tors (G-CSFs), such as pegfilgrastim, lipegfilgrastim, and short acting G-CSFs (i.e. 
filgrastim or lenograstim used in a 6-day regimen) for chemotherapy-induced 
febrile neutropenia (FN) in patients with non-Hodgkin’s Lymphoma (NHL) in 
Greece. MethOds: An economic model that comprises a decision tree and a Markov 
chain, consisting of two phases, was locally adapted to reflect outcomes from payer 
perspective. The analysis was conducted for a lifetime horizon, across two different 
chemotherapy schemes (CHOP and CHOP-R). Clinical inputs included baseline FN 
risks, efficacy of G-CSFs, mortality, effects of FN on relative dose intensity, as well 
as direct medical costs for drug acquisition and administration and FN manage-
ment. Input values were extracted from published studies while those for costs 
(2015 EUD) were obtained from local resources. Model outcomes were FN events 
avoided, and treatment strategies were compared by calculating incremental cost-
effectiveness ratios (ICERs) per FN event avoided. Results: PP with pegfilgrastim 
provided greater health benefits in terms of FN events (calculated by combining FN 
risk with the efficacy of G-CSFs: 0.164) followed by PP with lipegfilgrastim (0.243) 
and SP with pegfilgrastim (0.522). PP with pegfilgrastim was cost-effective versus 
SP with pegfilgrastim across all chemotherapy schemes (ICERs of € 7,490 for CHOP 
and € 7,781 for CHOP-R). SP with pegfilgrastim was cost-effective compared to SP 
with filgrastim (ICERs of € 1,657 for CHOP and € 1,836 for CHOP-R). SP with filgrastim 
was cost-effective compared to no prophylaxis (ICERs of € 1,404 for CHOP and € 1,585 
for CHOP-R). The rest of the alternatives were dominated by a less expensive and 
more effective strategy. cOnclusiOns: Our analysis finds PP with pegfilgrastim to 
be a cost-effective option for chemotherapy-induced FN in NHL patients in Greece.
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Objectives: The objective of this study was to develop a cost-effectiveness model 
from a third-party payer perspective to evaluate second-line treatment strate-
gies for NSCLC in the US and to investigate the value of ramucirumab+docetaxel 
(RAM+DOC) across histological subtypes. MethOds: Model comparators include 
the most commonly used second-line treatment regimens for NSCLC for which clini-
cal trial data were available in the squamous, nonsquamous, and overall population. 
We used a lifetime horizon, 3% cost discounting rate, and semi-Markov structure to 
account for time-dependent variation in probabilities of progression-free and overall 
survival. The structure of the model incorporated 21-day cycles and four health 
states including second-line treatment, third-line treatment, best supportive (pallia-
tive) care, and death. Clinical trial data were supplemented by other published data, 
when necessary. Probabilistic and one-way sensitivity analyses were conducted to 
test the robustness of findings. Results: Based on the results of this cost-effec-
tiveness analysis, RAM+DOC in the second-line treatment of patients may be con-
sidered a cost-effective option in the nonsquamous populations given an oncology 
willingness-to-pay threshold of $200,000 per life-year gained (ICER= $192,833 versus 
docetaxel alone). For the overall NSCLC population, comparators were limited and 
the incremental cost effectiveness ratio was slightly higher (ICER= $222,224 versus 
docetaxel). There were very limited data to evaluate the squamous population, and 
the ICER for RAM+DOC was high. The lack of complete data in the histological 
subgroups was a limitation; analyses were only possible for a subset of the com-
parators of interest. cOnclusiOns: The treatment patterns and cost data used to 
assumed to be a 50 year-old woman with HER2-positive metastatic breast cancer. 
Transition probability of each state in the model was estimated on the basis of the 
CLEOPATRA. As utility scores of Japanese metastatic breast cancer patients were not 
available, data from the NICE STA submission report were used. Costs were estimated 
on the basis of Japanese medical fee. Since our analysis was from the perspective of 
healthcare payer, only direct medical costs were included. Outcomes were meas-
ured in quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio 
(ICER) was calculated. Two percent annual discount rate was used both for costs and 
outcome. The model used a time horizon of 25 years. Results: Additional pertu-
zumab in combination with trastuzumab and docetaxel can gain more QALY (on 
average 0.85 QALY) than trastuzumab and docetaxel therapy. ICER of pertuzumab 
compared with control estimated to be about JPY 17 million per QALY (around £ 90,000, 
£ 1 = JPY 190). cOnclusiOns: Pertuzumab in combination with trastuzumab and 
docetaxel is not cost-effective in our analysis, when £ 50,000 or less is judged to be 
cost-effective as ICER.
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Objectives: To assess the cost-utility of first-line nilotinib vs imatinib in patients 
with chronic myeloid leukaemia (CML) eligible to start the treatment-free remis-
sion (TFR) phase in the Italian healthcare setting (NHS). MethOds: A previous 
cost-utility model, simulating a cohort of 20,000 patients individually followed, 
was adapted to the Italian NHS. CML patients could start treatment with nilotinib 
or imatinib while for both arms a second-line with nilotinb is expected according to 
the Italian clinical practice. Patients remaining on first-line at thirty-six months and 
with a BCR-ABL score less than MR4.5 are considered long-term responders and may 
enter the treatment free remission (TFR) phase. Model outcomes are expressed in 
Quality-Adjusted-Life-Years (QALYs) and life-years-gained (LYG). Clinical data were 
derived from ENEST-nd trial. A panel of experts in CML treatment provided input 
on healthcare resource consumption: routine visits, laboratory/instrumental tests, 
adverse events management and drug consumption. Costs - Euros (€ ) 2015 - were 
quantified using Hospital National Tariffs and ex-factory drug prices. The model 
assumes that generic imatinib and nilotib become available as of January 2017 
and July 2023,respectively, and therefore a 74% price discount for both drugs was 
included. Costs and outcomes were discounted at 3% according to Italian Guidelines 
for Economic Evaluations. Incremental cost-effectiveness ratios (ICERs) were calcu-
lated to estimate the incremental cost of a TFR patient with nilotinib. Results: An 
incremental number of 3,773 patients are eligible to TFR with nilotinib vs imatinib 
with € 33,748 total costs/patient. An improvement of +1.06 QALYs and +1.49 LYG is 
also observed in the nilotinib arm. The ICERs for nilotinib vs imatinib are € 39,935/
QALY and € 31,969/LYG. cOnclusiOns: The model shows that a greater number of 
patients enter TFR with nilotinib with acceptable ICERs vs imatinib.
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Objectives: A new human papillomavirus (HPV) vaccine protects against the 9 
HPV types responsible for 90% of HPV-related cancers (cervix, anus, vulva, vagina). It 
includes the 4 types contained in the quadrivalent (HPV 6,11,16,18) and 5 additional 
high-risk HPV types (HPV 31, 33, 45, 52, 58). The analysis aimed at estimating the 
incremental public health impact and cost-effectiveness of 2 different interven-
tions in Italy: 1) girl vaccination with a ninevalent HPV vaccine compared to a 
quadrivalent vaccine; 2) universal (girls and boys) vaccination programme with a 
ninevalent HPV vaccine compared to a quadrivalent vaccine. MethOds: A dynamic 
transmission model including a wide range of health and cost outcomes related to 
cervical, anal, vulvar, vaginal diseases and genital warts was calibrated to Italian epi-
demiological data. The clinical impact due to the 5 new types was included for cervi-
cal diseases only, producing conservative outcomes. In the base case, a two-dose 
schedule, lifelong vaccine type-specific protection and a vaccination coverage rate of 
71% for the 12-year old cohorts were assumed. A threshold of 30,000€ /QALY-gained 
was considered. Different prices assumptions were used for the ninevalent vaccine 
(from 0% to 40% higher than that of the quadrivalent HPV vaccine). Deterministic 
sensitivity analyses on key parameters (such as duration of protection, discount 
rate) were conducted. Results: Over 100 years, between 21,000 to 22,000 cervical 
cancers and between 272,600 and 288,790 pre-cancerous cervical lesions could be 
avoided with the implementation of a ninevalent vaccine. The cost-effectiveness 
ratio of the ninevalent vaccine is estimated to remain well below the threshold with 
all the different price assumptions considered. cOnclusiOns: Both scenarios with 
a ninevalent vaccine in Italy are estimated to be from cost saving to highly cost-
effective across a range of sensitivity analyses and are expected to further reduce 
the public health burden of HPV-related cancers and diseases.
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Health Insurance Service of Korea. All costs were measured in Korean won (KRW) and 
converted to US dollars (USD) using 2014 official exchange rate (1USD= 1,053.22KRW). 
Discount rate of 5% was applied to cost and effectiveness. Results: Based on com-
plete cytogenetic response rates at 12 month, Imatinib ($277,971) was less costly 
than Dasatinib ($388,232) and Nilotinib ($445,548). Life-year gains of Dasatinib (15.18 
LYs), were superior to other TKIs (Imatinib: 14.52 LYs, Nilotinib: 15.13 LYs), but ICER 
was $167,010 per LYs which far exceeds current willingness to pay level ($28,484) 
in Korea. Applying major molecular response rates at 12 month, the most effec-
tive strategy was Nilotinib ($416,513, 14.76 LYs), but its cost was the highest among 
others: Dasatinib ($365,602, 14.47 LYs) and Imatinib ($300,490, 13.8 LYs). The ICER of 
Dasatinib and Nilotinib was $98,483 and $170,431 per LYs respectively compared to 
Imatinib. cOnclusiOns: Given the current willingness to pay level of $28,959 in 
Korean setting, Imatinib (400 mg) was found out to be the most cost-effective strategy 
compared to Dasatinib (100mg) and Nilotinib (300 mg).
PCN161
Cost-EffECtivENEss of dirECtly mAilEd fobt kits to PrEvious 
rEsPoNdErs bEiNG rECAllEd for sCrEENiNG
Mittmann N1, Hassan S2, Patel J1, Tinmouth J1
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Sunnybrook Research Institute, 
Toronto, ON, Canada
Objectives: To conduct a cost-effectiveness analysis to evaluate whether the addi-
tion of a fecal occult blood test (FOBT) kit to a mailed invitation for recall compared 
to a mailed invitation for recall alone increases participation among patients who 
had responded previously to a mailed invitation in screening for colorectal cancer 
(CRC). MethOds: The perspective of the analysis will be that of the cancer agency 
in Ontario, Canada. Eligible patients (responders to the initial pilot study invita-
tion, FOBT negative, and now due for repeat screening) from 61 physicians were 
randomly allocated to one of the two interventions: (1) Mailed FOBT kit and mailed 
invitation for recall from their family physician (intervention group) OR (2) mailed 
invitation alone for recall (control group). Health system and program resources and 
costs associated with each group will be identified and quantified. Resources will 
be stratified into fixed costs (initial set-up costs including document development, 
programming for ongoing maintenance, etc.), variable or recurrent costs (costs of 
the kit, administrative costs, physician visits etc.) and staff costs (call centre sup-
port personnel and business analyst). Results: There are a total of 431 patients in 
the intervention group and 452 patients in the control group. Overall costs for each 
group will be determined, and the cost per patient will be reported. Cost drivers 
will be identified by conducting a series of univariate sensitivity analyses, including 
reducing the cost of the kit and using different assumptions for kit wastage. The 
results will show whether the addition of the FOBT kit to the mailed invitation is 
cost effective when compared to a mailed invitation only. cOnclusiOns: This cost 
effectiveness analysis will help in determining effective strategies for screening 
programs that are needed to reduce CRC mortality at a population level.
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Objectives: To assess the clinical and cost effectiveness of mammography for 
breast cancer screening in India MethOds: A systematic literature search was 
conducted in all the available scientific databases - Cochrane library, MEDLINE, 
PUBMED Science Direct, EMBASE, SCOPUS and Google Scholar for relevant studies. 
We identified 31 studies and literature filter started by scanning titles; abstracts as 
well as the content of the articles according to Inclusion criteria; finally 12 studies 
were included in quantitative synthesis (Meta analysis). We estimated risk of bias 
using Cochrane collaborating guidelines. Results: Review Manager 5.2 was used 
to do the data analysis and results are expressed in legible diagrams, considering 
all 12 studies with data from 4047721 participants, Risk Ratio was calculated (RR): 
0.71 (95% confidence Interval, CI: 0.67, 0.75). cOnclusiOns: Annual screening 
of female population above 30 years of age could reduce breast cancer associ-
ated mortality by 29% mainly due to early detection of breast cancer detection 
and subsequent early treatment pathways. The cost effectiveness is about Rs. 
19520/- per life year gained which is an excellent social return on investment on 
this technology.
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Objectives: Evaluation of cost-effectiveness and cost-utility of afatinib in 
patients with non-small cell lung cancer (NSCLC) with deletion in 19th exon of epi-
dermal growth factor receptor (EGFR) gene in 1st-line therapy. MethOds: Markov 
modeling was implemented to simulate clinical and economical outcomes of dif-
ferent strategies in treatment of naïve patients with NSCLC over 18 years old based 
on results of randomized clinical trials LUX-Lung 3 and LUX-Lung 6. Direct medical 
costs were considered. The time horizon of the analysis – 10 years. Compared 
drugs: afatinib, erlotinib, gefitinib and combination cisplatin/pemetrexed. Results 
were expressed in terms of quality-adjusted life years (QALY), life years (LY) gained 
and ICER (QALY). Results: Afatinib used as 1st-line treatment in patients with 
inform this model are US-specific and would require adaptation to be generalizable 
elsewhere. Depending on the threshold used by the decision maker, RAM+DOC 
may be a cost-effective option for the overall and nonsquamous NSCLC population.
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Objectives: Abiraterone (ABI) and enzalutamide (ENZ) have been recently approved 
for the treatment of docetaxel (DOC)-naïve metastatic castration-resistant prostate 
cancer (mCRPC) but the cost-effectiveness associated with sequencing of these 
agents remains unclear. The objective of this study was to compare the efficacy 
and drug costs of different treatment sequences considering the loss of efficacy 
associated to subsequent treatments in mCRPC patients. MethOds: Median overall 
survival (OS) and costs were estimated for the following sequences: (A) ABI-DOC-
CBZ; (B) ABI-DOC-ENZ; (C) ENZ-DOC-CBZ and (D) ENZ-DOC-ABI. OS and duration 
of treatment (DoT) estimates were based on data from clinical trials and adjusted 
according to literature review and expert clinical opinion, to account for potential 
efficacy loss after ABI or ENZ exposure as follows: DOC -10%; CBZ -10%; ENZ -40%; 
ABI -50%. The cost analysis included only drug costs and was undertaken from the 
perspective of the Spanish National Healthcare System. Incremental cost-effective-
ness ratios (ICERs) were calculated in terms of cost per life year gained (LYG) for 
the following comparisons: A-vs-B and C-vs-D. Uncertainties around efficacy and 
DoT assumptions were explored in a sensitivity analysis. Results: In the base 
case scenario, median OS estimates for patients treated with sequences A, B, C and 
D were 40.1, 37.5, 34.8 and 29.1 months, with respective costs of € 68,967, € 62,228, 
€ 60,766 and € 50,952. The ICERs were € 31,712/LYG for A vs B and € 20,697/LYG for C 
vs D. When reduction rates were applied only to OS but were not considered their 
influence on DoT, treatment sequences containing third-line CBZ were dominant vs 
sequences containing ENZ or ABI. cOnclusiOns: Sequences containing third-line 
CBZ were more effective than sequences containing third-line ABI or ENZ. Third-line 
CBZ after ABI-DOC or after ENZ-DOC could be considered as cost-effective compared 
to third-line ABI or ENZ.
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Objectives: To evaluate the cost-effectiveness of regorafenib compared to 
the standard of care (SoC), in the treatment of metastatic colorectal cancer in 
previously treated patients. MethOds: A cohort partition model demonstrating the 
progression of mCRC patients towards death and evaluating clinical and economi-
cal outcomes was adapted to the Turkish setting. Event and mortality rates were 
derived from the CORRECT clinical trial. An expert panel, with the participation of 
experts in colorectal cancer, was established for the adaptation of clinical data to 
Turkish practice. The analysis was undertaken from payer perspective. The time 
horizon was taken as life time period. Costs of each health state included year 2015 
local costs of medications, monitoring and events (TL/EUR currency rate was set 
at 2.9274; mid 2015). Incremental cost effectiveness ratios (ICER) per life year (LY) 
were calculated. Willingness-to-pay (WTP) threshold was set to two times of the 
local gross domestic product per capita per life years saved (adapted from World 
Health Organization definition) and was calculated as 18,481EUR. One-way sensi-
tivity analyses were conducted to test the robustness of the model. Results: The 
total cost of regorafenib was 2,173EUR higher compared to SoC. Regorafenib was 
associated with increment of 0.153 LYs, leading to an ICER of 14,188EUR/LY gained. 
Life years gained were 0.215 and 0.221 years in patients with wild type K-ras muta-
tion and patients with less than 4 lines of treatment, respectively. Accordingly, ICER 
values were lower (10,280EUR and 8,308EUR) than overall group in these subgroups. 
Sensitivity analyses showed that the cost-effectiveness results are fairly insensitive 
to most inputs. cOnclusiOns: Regorafenib, given its improvement in progression 
free survival and overall survival, and ICER values below WTP threshold, is suggested 
to be a cost-effective alternative in the treatment of metastatic colorectal cancer in 
previously treated patients in Turkey.
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Objectives: This study aims to evaluate cost effectiveness of currently available first-
line TKIs, Dasatinib (100mg), Nilotinib (600 mg) and Imatinib (400mg), in treatment of 
newly diagnosed CML patients in Korea. MethOds: We developed a Markov model 
model composed of four health states: response in chronic-phase (CP), no-response 
in CP, accelerated or blastic phase (AP/BP) and Death. Progression rate to AP/BP is 
assumed to be dependent on the presence of cytogenetic or molecular response to 
TKI at 12 month. Clinical effectiveness were obtained from DASISION and ENESTnd 
trials. In terms of cost, only direct medical costs (e.g. outpatient, hospitalisation and 
medication costs) with 5% of patient copayment were included into the study. Average 
medical cost of CML patients were calculated using claims data from the National 
